Pharmacodynamic characterization of rytvela, a novel allosteric anti-inflammatory therapeutic, to prevent preterm birth and improve fetal and neonatal outcomes.

Tiffany Habelrih,David-Étienne Tremblay,Erica Di Battista,Xin Hou, Allan Reuben, Béatrice Ferri,Sarah-Eve Loiselle,France Côté,Pénélope Abram,William D Lubell,Kelycia B Leimert,Christiane Quiniou,Sylvie Girard,David M Olson,Sylvain Chemtob

American journal of obstetrics and gynecology（2023）

引用 3|浏览7

暂无评分

摘要

The maximum efficacy of rytvela was achieved at 2 mg/kg/d with improved birth outcomes and prevented inflammatory up-regulation upon 36 hours (only) of treatment. Rytvela exhibited desirable properties for the safe prevention of preterm birth and fetal protection.

查看译文

关键词

cytokine,dose-response,duration of treatment,fetal protection,inflammation,interleukin 1,neonatal injury,neonatal mortality,prematurity,preterm labor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要